Trial reportJournal of immunotherapy (Hagerstown, Md. : 1997)
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Trial report in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00020397 (Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.International journal of molecular sciences · 2024Review
- Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.Biomaterials · 2018Article
- Immune targets and neoantigens for cancer immunotherapy and precision medicine.Cell research · 2017Review
- Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.Cancer immunology, immunotherapy : CII · 2014Article
- Review
- HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.Investigational new drugs · 2014Article
- Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Frontiers in immunology · 2013Article
- Trial watch: Peptide vaccines in cancer therapy.Oncoimmunology · 2012Article
- Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Oncoimmunology · 2012Article
- Vaccines as consolidation therapy for myeloid leukemia.Expert review of hematology · 2011Review
- Therapeutic cancer vaccines: are we there yet?Immunological reviews · 2011Review
- Tumor vaccines for breast cancer.Cancer investigation · 2009Review
- Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma.Journal of oncology · 2009Article
- HLA typing demands for peptide-based anti-cancer vaccine.Cancer immunology, immunotherapy : CII · 2008Article
- Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2008Article
- Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.The New England journal of medicine · 2008Article
- Identification and expression analysis of novel LAGE-1 alleles with single nucleotide polymorphisms in cancer patients.Journal of cancer research and clinical oncology · 2008Article
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Cancer vaccines as a therapeutic modality: The long trek.Cancer immunology, immunotherapy : CII · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
HLA class I-restricted peptides are often used in peptide vaccine regimens. There is strong evidence that many of these peptides can generate specific CD8 T-cell responses in vivo; however, only occasional objective clinical responses have been reported. To test whether provision of "help" would enhance antitumor immunity, the authors initiated a clinical trial in which patients with metastatic melanoma were immunized against the NY-ESO-1 tumor antigen, using an HLA-A2-restricted peptide (ESO-1:165V), an HLA-DP4-restricted peptide (NY-ESO-1:161-180), or both peptides given concomitantly. The first cohorts received only ESO-1:165V, using three vaccination schedules. Immunologically, most patients developed immune responses to the HLA-A2-restricted native ESO-1 epitope after vaccination. Peptide vaccine given daily for 4 days appeared to induce immunologic responses more rapidly than if given once a week or once every 3 weeks. In contrast, vaccination using the NY-ESO-1:161-180 peptide induced immune responses in only a few patients. Clinically, one patient who received NY-ESO-1:161-180 peptide alone had a partial response lasing 12 months. Concomitant vaccination with the HLA class II-restricted peptide did not alter the immune response to the HLA class I-restricted peptide form NY-ESO-1. However, vaccination with the HLA-A2-restricted epitope generated primarily T cells that did not recognize tumor after in vitro sensitization. This result raises questions about the use of synthetic peptides derived from NY-ESO-1 as a sole form of immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.